UBS Group Cuts Cooper Companies (NASDAQ:COO) Price Target to $66.00

Cooper Companies (NASDAQ:COO) had its target price cut by UBS Group from $75.00 to $66.00 in a research report report published on Thursday morning, Marketbeat reports. They currently have a neutral rating on the medical device company’s stock.

COO has been the topic of a number of other research reports. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the company an “equal weight” rating in a report on Thursday. Citigroup reiterated a “neutral” rating and set a $60.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Finally, Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $71.47.

Cooper Companies Stock Down 0.5%

COO stock opened at $53.91 on Thursday. The stock has a market capitalization of $10.25 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a 50-day moving average of $71.62 and a two-hundred day moving average of $69.70. Cooper Companies has a 52-week low of $51.01 and a 52-week high of $89.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the company posted $0.49 earnings per share. The firm’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities research analysts anticipate that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a stock repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors have recently bought and sold shares of the business. Avalon Trust Co bought a new stake in Cooper Companies in the 2nd quarter valued at $25,000. Root Financial Partners LLC lifted its holdings in shares of Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares during the period. SJS Investment Consulting Inc. lifted its holdings in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after acquiring an additional 187 shares during the period. Elevation Wealth Partners LLC boosted its position in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 375 shares in the last quarter. Finally, Continuum Advisory LLC acquired a new stake in shares of Cooper Companies during the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.